|
|
||||||||
lb619 |
1 Inflammation,
2 Biological Technologies, Wyeth, Cambridge, MA,
3 Neuroscience, Wyeth, Princeton, NJ,
4 Chemical and Screening Science, Wyeth, Pearl River, NY
ABSTRACT
Rapamycin is an immunosuppressive immunophilin ligand reported as having in vitro neuroprotective activity. WYE-592 and ILS-920, synthesized by modifying rapamycin at the mTOR binding region, showed reduced immunosuppressive activity and enhanced neuroprotective activities. Also, ILS-920 demonstrated efficacy in an in vivo stroke model. This stimulated our interest in identifying potential targets that may be important in post-ischemic recovery. Affinity precipitation from a dorsal root ganglia/neuroblastoma (F11) cell lysate revealed that ILS-920 predominantly binds to FKBP52 and the β-subunit of L-type voltage dependent Ca2+channels. Further, kinetic analysis demonstrated that ILS-920 had a 972-fold higher selectivity for FKBP52 vs. FKBP12 than that of rapamycin. The involvement of FKBP52 and the β-subunit in the mechanism of neurite outgrowth was established by gene deletions. Electrophysiological analysis showed that IL-920 reduced 49% of total Ca2+ current, and inhibited the L-type Ca2+channels in rat hippocampal neurons, in contrast to rapamycin. These data suggest that this dual functionality- FKBP52 binding that stimulates neurite outgrowth perhaps via modulation of glucocorticoid and other steroid receptors, and inhibition of Ca2+ channel function to prevent neuronal cell death- may contribute to the compounds efficacy in stroke models.
| ||||||||||||||||||||||||||||||||||||||||||||